Why that matters: cortisol and GLP-1 effectiveness are inversely linked, and perimenopausal estrogen decline dysregulates the HPA axis, raising baseline cortisol and driving hormonal belly fat redistribution that keeps women stuck at a normal BMI with real metabolic dysfunction

The names and codes currently associated with retatrutide include: International Nonproprietary Name (INN): Retatrutide this is the official generic name assigned by the World Health Organisation (WHO) and recorded in the WHO INN list, to facilitate consistent identification across countries Development code: LY3437943 this alphanumeric identifier was assigned by Eli Lilly and Company, the pharmaceutical manufacturer developing the compound, and is frequently used in clinical trial documentation and scientific publications [1] [2] Descriptive terms: Sometimes referred to informally in research contexts as a GLP-1/GIP/glucagon triple agonist or a triagonist , though these are descriptive terms rather than formal names No proprietary brand name (such as those used for semaglutide Ozempic, Wegovy or tirzepatide Mounjaro) has been officially assigned or approved for retatrutide at the time of writing

All medications have side effects, and the anti-obesity drugs are no exception, says Christopher McGowan, MD, a gastroenterologist, obesity medicine specialist, and founder of True You Weight Loss
Wegovy is contraindicated in pregnancy and breastfeeding
Ozempic and Wegovy Pens Are Different Everything above applies to compounded semaglutide in a vial